BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16250252)

  • 1. Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats.
    Huang JM; Weng WY; Huang XB; Ji YH; Chen E
    Eur J Drug Metab Pharmacokinet; 2005; 30(3):165-70. PubMed ID: 16250252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.
    Xing JF; You HS; Dong YL; Lu J; Chen SY; Zhu HF; Dong Q; Wang MY; Dong WH
    Acta Pharmacol Sin; 2011 May; 32(5):655-63. PubMed ID: 21516133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A UPLC-ESI-MS/MS Method for Simultaneous Quantitation of Chlorogenic Acid, Scutellarin, and Scutellarein in Rat Plasma: Application to a Comparative Pharmacokinetic Study in Sham-Operated and MCAO Rats after Oral Administration of
    Chen S; Li M; Li Y; Hu H; Li Y; Huang Y; Zheng L; Lu Y; Hu J; Lan Y; Wang A; Li Y; Gong Z; Wang Y
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30037063
    [No Abstract]   [Full Text] [Related]  

  • 4. Determination of aglycone conjugated metabolites of scutellarin in rat plasma by HPLC.
    Huang J; Li N; Yu Y; Weng W; Huang X
    J Pharm Biomed Anal; 2006 Feb; 40(2):465-71. PubMed ID: 16181763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two major urinary metabolites of scutellarin in rats.
    Qiu F; Xia H; Zhang T; Di X; Qu G; Yao X
    Planta Med; 2007 Apr; 73(4):363-5. PubMed ID: 17354170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between scutellarin and valsartan in rats.
    Cui MY; Tian CC; Ju AX; Zhang CT; Li QH
    Yao Xue Xue Bao; 2013 Apr; 48(4):541-6. PubMed ID: 23833943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and identification of ten metabolites of breviscapine in rat urine.
    Xia H; Qiu F; Zhu S; Zhang T; Qu G; Yao X
    Biol Pharm Bull; 2007 Jul; 30(7):1308-16. PubMed ID: 17603172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration.
    Chen X; Cui L; Duan X; Ma B; Zhong D
    Drug Metab Dispos; 2006 Aug; 34(8):1345-52. PubMed ID: 16714374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inhibition capability of scutellarein and scutellarin towards important liver UDP-glucuronosyltransferase (UGT) isoforms.
    Ma GY; Cao YF; Hu CM; Fang ZZ; Sun XY; Hong M; Zhu ZT
    Phytother Res; 2014 Mar; 28(3):382-6. PubMed ID: 23620377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in studies on pharmacokinetics of scutellarin and scutellarein].
    Liu J; Xiong Y
    Zhongguo Zhong Yao Za Zhi; 2009 Dec; 34(24):3165-8. PubMed ID: 20352990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism profile of scutellarin in urine following oral administration to rats by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry.
    Liu Q; Shi Y; Wang Y; Lu J; Cong W; Luo G; Wang Y
    Talanta; 2009 Nov; 80(1):84-91. PubMed ID: 19782195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats.
    Chen X; Jin J; Chen Y; Peng L; Zhong G; Li J; Bi H; Cai Y; Huang M
    Biopharm Drug Dispos; 2015 Jan; 36(1):64-8. PubMed ID: 25256597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic and tissue distribution study of scutellarin in rats].
    You HS; Dong YL; Xing JF; Zhang CL; Wang MY
    Zhongguo Zhong Yao Za Zhi; 2007 Aug; 32(16):1688-92. PubMed ID: 18027669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics and metabolites of scutellarin in normal and model rats].
    Gao HM; Wang ZM; Tian J
    Yao Xue Xue Bao; 2005 Nov; 40(11):1024-7. PubMed ID: 16499088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin.
    Yang X; Miao X; Cao F; Li S; Ai N; Chang Q; Lee SMY; Zheng Y
    J Pharm Sci; 2014 Nov; 103(11):3576-3584. PubMed ID: 25187229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of scutellarin and its derivant scutellarin ethyl ester in rats].
    Zhu LW; Liu XQ; Feng J; Gao HM; Yi H; Wang ZM; Meng QJ
    Zhongguo Zhong Yao Za Zhi; 2013 Oct; 38(19):3373-7. PubMed ID: 24422411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the pharmacokinetics of scutellarin in dogs].
    Jiang XH; Li SH; Lan K; Yang JY; Zhou J
    Yao Xue Xue Bao; 2003 May; 38(5):371-3. PubMed ID: 12958843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption and disposition of scutellarin in rats: a pharmacokinetic explanation for the high exposure of its isomeric metabolite.
    Gao C; Chen X; Zhong D
    Drug Metab Dispos; 2011 Nov; 39(11):2034-44. PubMed ID: 21810967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous determination of three glucuronide conjugates of scutellarein in rat plasma by LC-MS/MS for pharmacokinetic study of breviscapine.
    Wang X; Xia H; Liu Y; Qiu F; Di X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Aug; 965():79-84. PubMed ID: 24999248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats.
    Lin LL; Liu AJ; Liu JG; Yu XH; Qin LP; Su DF
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):327-32. PubMed ID: 17878763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.